JP2022518479A - 脂質結合体化コア足場を使用する高密度リポタンパク質模倣ナノ粒子 - Google Patents
脂質結合体化コア足場を使用する高密度リポタンパク質模倣ナノ粒子 Download PDFInfo
- Publication number
- JP2022518479A JP2022518479A JP2021542150A JP2021542150A JP2022518479A JP 2022518479 A JP2022518479 A JP 2022518479A JP 2021542150 A JP2021542150 A JP 2021542150A JP 2021542150 A JP2021542150 A JP 2021542150A JP 2022518479 A JP2022518479 A JP 2022518479A
- Authority
- JP
- Japan
- Prior art keywords
- hdl
- spherical
- dna
- core
- spherical hdl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 61
- 150000002632 lipids Chemical class 0.000 title claims abstract description 46
- 108010010234 HDL Lipoproteins Proteins 0.000 title claims description 196
- 102000015779 HDL Lipoproteins Human genes 0.000 title claims description 196
- 238000000034 method Methods 0.000 claims abstract description 82
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 201000011510 cancer Diseases 0.000 claims abstract description 28
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 15
- 102000003945 NF-kappa B Human genes 0.000 claims abstract description 13
- 108010057466 NF-kappa B Proteins 0.000 claims abstract description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 124
- 235000012000 cholesterol Nutrition 0.000 claims description 58
- 108020004414 DNA Proteins 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 40
- 108091034117 Oligonucleotide Proteins 0.000 claims description 38
- 150000003904 phospholipids Chemical class 0.000 claims description 38
- 239000002773 nucleotide Substances 0.000 claims description 27
- 125000003729 nucleotide group Chemical group 0.000 claims description 27
- 150000003384 small molecules Chemical class 0.000 claims description 23
- 125000000524 functional group Chemical group 0.000 claims description 22
- 102000007592 Apolipoproteins Human genes 0.000 claims description 21
- 108010071619 Apolipoproteins Proteins 0.000 claims description 21
- BVSVQXDPZJOCEV-UHFFFAOYSA-N 1-azido-4-[tris(4-azidophenyl)methyl]benzene Chemical group C1=CC(N=[N+]=[N-])=CC=C1C(C=1C=CC(=CC=1)N=[N+]=[N-])(C=1C=CC(=CC=1)N=[N+]=[N-])C1=CC=C(N=[N+]=[N-])C=C1 BVSVQXDPZJOCEV-UHFFFAOYSA-N 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- QRZUPJILJVGUFF-UHFFFAOYSA-N 2,8-dibenzylcyclooctan-1-one Chemical compound C1CCCCC(CC=2C=CC=CC=2)C(=O)C1CC1=CC=CC=C1 QRZUPJILJVGUFF-UHFFFAOYSA-N 0.000 claims description 16
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 15
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 102000053602 DNA Human genes 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 12
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 150000001540 azides Chemical group 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 239000002502 liposome Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 239000000232 Lipid Bilayer Substances 0.000 claims description 5
- 150000001345 alkine derivatives Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108020004635 Complementary DNA Proteins 0.000 claims description 4
- 238000010804 cDNA synthesis Methods 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000002356 single layer Substances 0.000 claims description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 25
- 238000003786 synthesis reaction Methods 0.000 abstract description 23
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 13
- 238000012512 characterization method Methods 0.000 abstract description 6
- 239000007779 soft material Substances 0.000 abstract description 4
- 230000002194 synthesizing effect Effects 0.000 abstract description 3
- 239000011162 core material Substances 0.000 description 130
- 210000004027 cell Anatomy 0.000 description 46
- 239000002245 particle Substances 0.000 description 32
- 239000002953 phosphate buffered saline Substances 0.000 description 28
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- -1 Cholesteryl ester Chemical class 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 24
- 201000010099 disease Diseases 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 239000002609 medium Substances 0.000 description 16
- 208000011580 syndromic disease Diseases 0.000 description 16
- 239000004698 Polyethylene Substances 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 210000002540 macrophage Anatomy 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 230000032258 transport Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000004007 reversed phase HPLC Methods 0.000 description 9
- 230000001363 autoimmune Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 8
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 7
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000006384 oligomerization reaction Methods 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000000527 sonication Methods 0.000 description 7
- AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000004624 confocal microscopy Methods 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000003917 TEM image Methods 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000010409 thin film Substances 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 108010055297 Sterol Esterase Proteins 0.000 description 4
- 102000000019 Sterol Esterase Human genes 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- PYDIBDVAHXFICD-TYSIZKDBSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-[2-[2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]ethoxy]ethoxy]ethyl]carbamate Chemical compound C1=C([N+]([O-])=O)C2=NON=C2C(NCCOCCOCCNC(=O)O[C@@H]2CC3=CC[C@H]4[C@@H]5CC[C@@H]([C@]5(CC[C@@H]4[C@@]3(C)CC2)C)[C@H](C)CCCC(C)C)=C1 PYDIBDVAHXFICD-TYSIZKDBSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000012062 aqueous buffer Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002983 circular dichroism Methods 0.000 description 4
- 238000001142 circular dichroism spectrum Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 239000013554 lipid monolayer Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 239000002086 nanomaterial Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 150000008300 phosphoramidites Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 3
- DLWLXTLRGQWGPC-UHFFFAOYSA-N 10,13-dimethyl-17-[1-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]propan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2CC(O)CCC2(C)C(CCC23C)C1C3CCC2C(C)CNC1=CC=C([N+]([O-])=O)C2=NON=C12 DLWLXTLRGQWGPC-UHFFFAOYSA-N 0.000 description 3
- 238000008620 Cholesterol Assay Methods 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 3
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001840 cholesterol esters Chemical class 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 229940124447 delivery agent Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000036473 myasthenia Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 2
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 2
- 102000013918 Apolipoproteins E Human genes 0.000 description 2
- 108010025628 Apolipoproteins E Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 108010021075 HDL2 Lipoproteins Proteins 0.000 description 2
- 208000001204 Hashimoto Disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 108091005487 SCARB1 Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 230000004141 reverse cholesterol transport Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000003345 scintillation counting Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 1
- XKKCQTLDIPIRQD-JGVFFNPUSA-N 1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 XKKCQTLDIPIRQD-JGVFFNPUSA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- 101150092476 ABCA1 gene Proteins 0.000 description 1
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 description 1
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000380490 Anguina Species 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 108010061118 Apolipoprotein A-V Proteins 0.000 description 1
- 102000011936 Apolipoprotein A-V Human genes 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 108010076807 Apolipoprotein C-I Proteins 0.000 description 1
- 102000011772 Apolipoprotein C-I Human genes 0.000 description 1
- 108010024284 Apolipoprotein C-II Proteins 0.000 description 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 description 1
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 1
- 102000013933 Apolipoproteins D Human genes 0.000 description 1
- 108010025614 Apolipoproteins D Proteins 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 201000002827 Balo concentric sclerosis Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000009766 Blau syndrome Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DJSXIWXIOUHBRL-ICBMVRCQSA-N CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)SC(C)O)OC(=O)CCCCCCCCCCCCCCC Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)SC(C)O)OC(=O)CCCCCCCCCCCCCCC DJSXIWXIOUHBRL-ICBMVRCQSA-N 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010252 Concentric sclerosis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 208000016905 Hashimoto encephalopathy Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000029470 Hughes-Stovin syndrome Diseases 0.000 description 1
- 208000010152 Huntington disease-like 3 Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 208000029400 Inclusion myopathy Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000012309 Linear IgA disease Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042276 Subacute endocarditis Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108091061763 Triple-stranded DNA Proteins 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 1
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- VUBTYKDZOQNADH-UHFFFAOYSA-N acetyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)=O VUBTYKDZOQNADH-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000005022 aminoacridines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 108010073614 apolipoprotein A-IV Proteins 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 208000001974 autoimmune enteropathy Diseases 0.000 description 1
- 201000004339 autoimmune neuropathy Diseases 0.000 description 1
- 201000005011 autoimmune peripheral neuropathy Diseases 0.000 description 1
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 description 1
- 206010071572 autoimmune progesterone dermatitis Diseases 0.000 description 1
- 208000029407 autoimmune urticaria Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000003236 bicinchoninic acid assay Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000003056 complement component 2 deficiency Diseases 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 101150014604 cpg-3 gene Proteins 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 1
- 229950010333 exalamide Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000001031 fetal erythroblastosis Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 125000000879 imine group Chemical group 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 125000000885 organic scaffold group Chemical group 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 125000000830 polyketide group Chemical group 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003313 saccharo lipids Chemical class 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 108091005484 scavenger receptor class B Proteins 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- HOMYIYLRRDTKAA-IXWJMURKSA-N soya-cerebroside II Natural products CCCCCCCCCCCCCC[C@H](O)C(=O)N[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@@H](O)C=CCCC=CCCCCCCCCC HOMYIYLRRDTKAA-IXWJMURKSA-N 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
- A61K47/6909—Micelles formed by phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本発明は、Air Force Office of Scientific Research(AFOSR)によって付与された契約番号FA9550-13-1-0192およびNational Institutes of Healthによって付与された助成金番号AG062999の下で政府支援を得て行われた。政府は、本発明において一定の権利を有する。
本出願は、米国特許法第119条(e)の下で、2019年1月24日出願の米国仮特許出願第62/796534号(その全内容は、本明細書に参考として援用される)の優先権を主張する。
ナノ粒子は、ミクロン未満のサイズドメインにあり、物質をそれらのバルク形態と比較して、優れたものにする特有のサイズ依存特性を有する。ナノ粒子と関連する進歩した化学的および物理的特性は、生物学および医療の分野においてそれらの広範な用途をもたらした。高密度リポタンパク質(HDL)は、血液中で循環する動的ナノ粒子である。
本開示は、成熟ヒトHDLと一致するサイズ、形状、表面の化学的性質、組成、タンパク質構造、およびコレステロール輸送特性を有するソフトコアHDL様ナノ粒子の合成を示す。脂質結合体化(LC)したHDL NPは、細胞コレステロールを除去および送達し、炎症を低減するために関連する細胞タイプを標的化し、ヒトHDLの顕著な機能を再現する。LC HDL NPの合成は簡単であり、時間のかかるかつコストのかかる酵素成熟工程を要しないことから、これらのナノ粒子は、次世代のHDLベースの治療剤の強力な候補であると判明することが認識される。
高密度リポタンパク質(HDL)は、コレステロールを運び、特定の細胞タイプを標的化し、そして多くの疾患プロセスにおいて重要な役割を果たす天然の循環するナノ粒子である。結果として、合成HDL摸倣物は、有望な治療剤になった。しかし、今日までのアプローチは、最も存在量が豊富なHDL種であり、特定の臨床上重要である球状HDLの重要な特徴を再現することができなかった。
別段述べられなければ、全ての試薬および試薬グレード溶媒を、Sigma-Aldrich(Milwaukee, WI)から購入し、受容したまま使用した。全ての脂質- 1,2-ジパルミトイル-sn-グリセロ-3-ホスホエタノールアミン-N-ジベンゾシクロオクチル(DBCO PE)および1,2-ジパルミトイル-sn-グリセロ-3-ホスホコリン(DPPC)- ならびに蛍光コレステロール(22-(N-(7-ニトロベンゾ-2-オキサ-1,3-ジアゾール-4-イル)アミノ)-23,24-ビスノル-5-コレン-3β-オール((NBD)-コレステロール))を、Avanti Polar Lipids(Alabaster, AL)から得た。ApoA-Iタンパク質を、MyBioSource(San Diego, CA)から得た。全ての化学物質を、さらに精製せずに使用した。ウルトラピュア脱イオン(DI)H2O(18.2MΩ・cm 抵抗率)を、Milliporeシステム(Milli-Q Biocel)から得た。テトラキス(4-アジドフェニル)メタン1および脂質ホスホルアミダイト2を、以前に公開した手順に従って合成した。
a. DNA-PL4コアの合成
a-1. 9-SMDH4および18-SMDH4の合成および精製
9マーおよび18マーDNAアームとの低分子-DNAハイブリッド(SMDH)(それぞれ、9-SMDH4(配列番号1)および18-SMDH4(配列番号2))を、以前に公開した手順3に従って合成および精製した。この研究において使用されるDNA配列を、表2に列挙する。SMDH調製において形成した種々の生成物を同定するために、粗製SMDHの集めたサンプルのアリコートを、先ず、分析用RP-HPLCカラム(本明細書中の材料および計装の節を参照のこと)、および95:5 v/v 0.1M TEAA(水性):MeCN(TEAA(水性)=酢酸トリエチルアンモニウム、水性溶液)で開始し、60:40 v/v 0.1M TEAA(水性):MeCNへと35分間かけて(+1 容積% MeCN/分の傾きで)増大させ、流量1mL/分での勾配法を使用して分析した。次いで、全サンプルを、半分取用RP-HPLCカラム(本明細書中の材料および計装の節を参照のこと)、および95:5 v/v 0.1M TEAA(水性):MeCNで開始し、60:40 v/v 0.1M TEAA(水性):MeCNへと70分間かけて(+0.5 容積% MeCN/分の傾きで。ここではより緩やかな勾配を使用して、ピークの適切な分離を確実にした)増大させ、流量3mL/分での勾配法を使用して精製に供した。その集めたSMDH4生成物の正体をMALDI-ToF MS分析によって確認し(図6~7の挿入図)、その純度を、前述の分析用RP-HPLC溶媒プログラムとともに分析用RP-HPLCを使用して再評価した(図6~7)。
表面に付着したアデニン(Glen Research, dA-CPG # 20-2001-10(1000Å、28μmol/g))またはチミン(Glen Research, dT-CPG # 20-2031-10(1000Å、27μmol/g))のいずれかの1μmolを有する孔制御ガラス(CPG)ビーズを使用して、合成を3’方向から行った。そのCPGビーズを、1μmol 合成カラムの中に入れ、次いで、3’-ホスホルアミダイト(Glen Research, dA-CEホスホルアミダイト # 10-1000-C5、Ac-dC-CEホスホルアミダイト # 10-1015-C5、dmf-dG-CEホスホルアミダイト # 10-1029-C5、dT-CEホスホルアミダイト # 10-1030-C5)を、Expedite 8909合成機で標準的な1μmol プロトコールを使用して添加して、CPG-3’-ssDNAを作製した(配列については表2を参照のこと)。脂質ホスホルアミダイトを、ssDNA鎖の5’末端に付加し、次いで、ビーズを、乾燥窒素ガス流で乾燥させ、水性の新鮮なAMA溶液(30重量% 水性水酸化アンモニウム溶液および40重量% 水性メチルアミン溶液の1:1 v/v 混合物を1mL)を含むバイアル中に入れた。次いで、そのバイアルに蓋をし、65℃において15分間加熱して、DNA-脂質結合体を、固体支持体から切断した。次いで、アンモニアおよびメチルアミン副生成物を、特徴的なアンモニア臭が消失するまで、バイアルの内容物に乾燥窒素ガス流を通すことによって除去した。残りの液体(これは、粗製DNA-脂質結合体を含む)を、ピペットで集め、残りのビーズを、ウルトラピュア脱イオン水(200μL)でさらに抽出した。その抽出物を、粗製DNA-脂質結合体の最初の溶液と合わせ(最終的には全容積0.4mLを得る)、0.45μm ナイロンシリンジフィルター(Acrodisc(登録商標) 13mmシリンジフィルター# PN 4426T)を通して濾過した。粗製生成物の集めたサンプルを、分析用RP-HPLC(図8~9)および95:5 v/v 0.1M TEAA(水性):MeCN(TEAA(水性)=酢酸トリエチルアンモニウム、水性溶液)で開始し、100% MeCNへと50分間かけて増大させ(+1.9容積% MeCN/分の傾きで)、流量1mL/分での勾配法を使用して精製に供した。その集めた生成物の正体をMALDI-ToF MS分析によって確認し(図8~9の挿入図)、その純度を、変性ポリアクリルアミドゲル電気泳動(PAGE)によって検証した(図9)。
TAMg緩衝溶液(40mM Tris、20mM 酢酸、および7.5mM MgCl2; pH7.4)中の、調製したとおりのSMDH4およびその相補的DNA-脂質結合体の等モル混合物を、0.5mL エッペンドルフチューブへと添加した。次いで、得られた溶液を90℃へと加熱ブロック(Thermomixer R; Eppendorf, Hauppauge, NY)で加熱し、そこで5分間維持して、全ての最初のDNA相互作用を除去した。次いで、加熱ブロックへの出力を切って、その溶液を室温へと3時間かけてゆっくりと冷却させた(この装置の代表的な冷却プロフィールに関しては、Yildirim, I.; Eryazici, I.; Nguyen, S. T.; Schatz, G. C. J. Phys. Chem. B 2014, 118, 2366-2376の補足情報の図S16を参照されたい)。
b-1. テトラキス(4-アジドフェニル)メタンの合成
テトラキス(4-アジドフェニル)メタンを、以前に公開した手順1に従って合成した。
PL4コア材料を、1,2-ジパルミトイル-sn-グリセロ-3-ホスホエタノールアミン-N-ジベンゾシクロオクチル(DBCO PE)と四面体低分子コア(テトラキス(4-アジドフェニル)メタン)との銅フリークリックケミストリー結合体化によって合成した(図11)。代表的なクリックケミストリー反応において、DBCO PEおよびテトラキス(4-アジドフェニル)メタンを各々、N,N-ジメチルホルムアミド(DMF)(Sigma Aldrich)中に0.1重量%で溶解し、DMF中、DBCO PE 対 テトラキス(4-アジドフェニル)メタンの10:1モル比で混合した。その反応混合物を、3回の交互になったボルテックスおよび浴超音波処理に供し、次いで、室温において、24時間ボルテックスして反応させた。次いで、エレクトロスプレーイオン化質量分析法を使用して、得られた生成物を特徴づけた(図12)。
ナノ粒子集合を、1,2-ジパルミトイル-sn-グリセロ-3-ホスホコリン(DPPC)リポソームを最初に調製することによって行った。DPPCを、5mL ガラスバイアルの中で、クロロホルム中0.1重量%において溶解した。次いで、薄いフィルムを、N2ガスでその溶媒をエバポレートすることによって生成した。そのフィルムを、デシケーターの中で>2時間、減圧下でさらに乾燥させた。次いで、リポソームを、浴超音波処理およびボルテックスを交互に行いながら、リン酸緩衝化食塩水(PBS: 10mM ホスフェートおよび137mM NaCl、pH=7.4)中で、DPPC濃度1mMにおいてその薄いフィルムを再懸濁することによって生成した。PL4 HDL NPに関しては、PL4コア足場を、DPPCに関して上記で記載されるその同じ様式において、DMF中の0.1重量% 溶液から薄いフィルムを生成することによって調製した。DNA-PL4 HDL NPに関しては、コア足場を、オリゴヌクレオチドによって付与されたコアの改善された水への溶解度に起因して、TAMg緩衝溶液(40mM Tris、20mM 酢酸、および7.5mM MgCl2; pH=7.4)中で開始した。粒子集合を開始するために、非足場ナノ粒子構成要素を、次いで、そのコア足場へと逐次的に添加した。代表的な集合において、40nmolのDPPCを、2nmol 脂質結合体コア足場(PL4またはDNA-PL4のいずれか)に添加し、続いて、4nmolのapoA-1を添加した(DPPCおよびapoA-1はともに、PBS中に予め懸濁しておいた)。次いで、その懸濁物を、PBSにおいて、PBS中最終コア濃度10μMへと希釈した。その懸濁物を、3回の交互になった浴超音波処理(90s オン、30s オフ)およびボルテックスに供し、氷上で>30分間緩和した。次いで、その粒子を濾過し、0.5mL 50kDa MWCOスピンカラム(MilliPore)を使用して濃縮した。そのカラムを、PBS中で10分間、10,000×gにおいて4℃で先ずすすぎ、その後、同じ条件下でその粒子を3回スピン濾過した。500μlのPBSを、各スピン後にカラムに添加し、その結果、各粒子懸濁物の溶媒は、スピン濾過後にPBSであり、TAMg緩衝液は、DNA-PL4 HDL NPの溶液から除去された。各回の濾過後に、その粒子を、デスクトップ遠心分離によって遠心分離して、いかなる凝集物をも除去した。最終回の濾過後に、小容積の濃縮粒子(約20μL)を、PBS中100~200μlへと希釈し、そのタンパク質濃度を、BCA試薬とともに37℃で30分間インキュベートした後に、562nmの吸光度を分光光度計で測定して、ビシンコニン酸アッセイ(BCA)によって決定した。次いで、その粒子は、直ぐに使用したか、または短期間の保存のために4℃に置いた。
コントロールサンプルを調製して、LC HDL NP集合プロセス、ならびに脂質結合体化コア足場およびapoA-1に対するその依存性を調査した。コア+apoA-1なしの足場コントロールを、上記で記載されるとおりのDPPCリポソームを作製することによって調製した(本明細書中の合成の節を参照のこと)。次いで、DPPCリポソームを、LC HDL NPにおけるものと同じ濃度およびモル比でコア足場に添加したところ、PL4足場は薄いフィルムになり、DNA-PL4足場は、水性緩衝液(PBS)中にあった。次いで、その混合物を、3回の交互になった超音波処理およびボルテックスに供し、濾過し、上記のように50kDa MWCOスピンカラムを通して濃縮した。apoA-1およびDPPC単独コントロールは、コア足場なしで同じ様式で集合した。
グリッド準備のために、サンプルを、PBS中1~2μM タンパク質の濃度で調製し、UV処理炭素コーティング銅300メッシュグリッド(Electron Microscopy Services)上にドロップキャストし、ドラフトチャンバ(chemical fume hood)の中で風乾した。そのグリッドをPBSで2回洗浄し、2% 酢酸ウラニルで20秒間、2回染色し、次いで、PBSで3回洗浄し、風乾し、その後画像化した。画像化を、80kVで作動するFEI Tecnai Spirit TEMを使用して行った。
円偏光二色性を、JASCO J-815 CD分光計を使用して行った。全てのサンプルを、蒸留水中で75μg/mL タンパク質に希釈した。1つのサンプルの3つの累積からスペクトルを得た。二次構造データを、分析アルゴリズムCONTINを走らせるCDProソフトウェアパッケージを使用して獲得した。種々の可溶性タンパク質参照セットを使用して、3回の別個の分析を行った。表1に報告される値は、これら3回の分析の平均±SEM結果を反映する。
a. タンパク質定量。 ナノ粒子および天然HDLのタンパク質含有量を定量するために、本発明者らは、市販のビシンコニン酸(BCA)アッセイ(Thermo Fisher)を、製造業者の指示に従って使用した。簡潔には、本発明者らは、BCA試薬溶液を使用して、96ウェルプレートの中にウシ血清アルブミン(BSA)サンプルを最終容積80μl/ウェルへと0.125mg/mLから2mg/mLまで希釈することによって、タンパク質標準曲線を作成した。ナノ粒子サンプルを、同じ様式で希釈した;標準およびサンプルを、40倍希釈した。標準を二連でプレートし、サンプルを三連でプレートした。プレートを、30分間、37℃においてインキュベートし、次いで、562nmの吸光度を、Synergyプレートリーダーを使用して測定した。
a. 架橋された粒子およびタンパク質サンプルの調製。 架橋剤、スベリン酸ビス[スルホスクシンイミジル](BS3)(Sigma Aldrich)を使用して、イムノブロットを介する検出の前に、集合の際にLC HDL NPにおけるapoA-1のいかなるより高次のオリゴマー化状態をも安定化させた。ここで使用される方法を、以前に報告したプロトコール4から適合させた。LC HDL NPを、上記のように調製し、PBS中50μg/mL タンパク質へと希釈した。次いで、BS3架橋剤を、2.5mMの最終BS3濃度になるようにLC HDL NPに添加し、その反応を、30分間、室温において進めた。apoA-1オリゴマーラダーを生成するために、脂質非含有純粋apoA-1(MyBioSource)をPBS中で透析し、次いで、BS3(0.25mM)で高タンパク質濃度(500μg/mL)において4時間、室温での架橋に供した。0.5M トリス塩基を使用して、その架橋反応を停止した(45mM 最終)。
a. 流出アッセイ: 流出実験のために、本発明者らは、当該分野で基準のアッセイ、J774マクロファージからのトリチウム標識コレステロール(H3-chol)の流出を使用した。J774マクロファージを、少なくとも2継代にわたって培養し、その後、1日目に、RPMI、10% ウシ胎仔血清(FBS)、1% ペニシリン-ストレプトマイシン(PenStrep)中で24ウェルプレートにおいて150,000細胞/ウェルで播種した。H3-cholのエタノールストックを、無菌条件下で扱った。H3-cholストックをエバポレートし、1mLのエタノール中に再溶解し、37℃で60分間インキュベートした。次いで、その溶液を再びエバポレートし、50μL エタノール中に再溶解し、37℃で30分間インキュベートした。次いで、熱不活化FBS(Corning, NY)をH3-chol溶液に添加し、4℃において一晩インキュベートした。2日目に、1% PenStepおよび2μg/mL Sandoz(Sigma-Aldrich, St. Louis, MO)を含む無血清RPMIを、上記H3-chol含有FBSに添加して、RPMI中、2μCi/mL H3-chol、5容積% FBSの最終標識培地を得た。Sandozが、H3-cholのエステル化を防止するために使用されるACATインヒビターであることに注意のこと。培地を24ウェルプレートから吸引し、500μLのH3-chol標識培地を添加した(1μCi/ウェル)。標識を、24時間にわたって進めた。3日目に、標識培地を除去し、細胞を、MEM、25μM HEPESで2回洗浄し、アップレギュレーション培地(RPMI、1% PenStrep、300μM cAMP、2μg/mL Sandoz、1% BSA)を添加して、標準コレステロール流出レセプターABCA1をアップレギュレートした(注: cAMP(-)流出アッセイ(図4D)に関しては、この培地を、SR-B1依存性流出を調査するために、cAMPなしで添加した)。アップレギュレーションを、24時間にわたって進め、その後、流出培地を添加した。ナノ粒子およびコントロールを含む流出サンプルを、無血清培地(MEM、25μM HEPES、1% PenStrep)中に調製して、血清コレステロールキャリアによる非特異的H3-chol流出を低減させた。細胞をMEM、25μM HEPES中で2回洗浄し、流出培地を、処理レジメンに従って各ウェルに添加した。流出を、4時間にわたって進めた。次いで、流出培地を除去し、真空濾過し、シンチレーション計数のために3mL UltimaGoldシンチレーション液に添加した。H3-chol搭載マクロファージの別個の三連のコホートを洗浄し、風乾し、イソプロパノール中で室温においてインキュベートして、流出の最初にt=0で全コレステロールの尺度としてH3-cholを抽出した。PBS処理コントロールコホートをベースラインとして使用し、次いで、これらのサンプルに関して得た計数を、実験群から差し引いて、ベースライン補正した計数を得た。次いで、流出パーセンテージを、流出培地のベースライン補正した計数 対 t=0マクロファージの計数の比として計算した。これは、4時間の処理の過程にわたって細胞から除去されたH3-cholの画分が拡散単独に起因しないことを示す。
a. 共焦点顕微鏡検査法。 HepG2細胞を、10% FBSおよび1% PenStrepを含むダルベッコ改変イーグル培地(DMEM)中で培養した。処理の1日前に、細胞を、24ウェルプレートにおいてガラスカバースリップの上に100,000細胞/ウェルでプレートした。処理日に、細胞をPBSで3回洗浄し、次いで、5μg/mL NBD-コレステロールを含む新鮮な培地を、処理レジメンに従って、送達薬剤ありまたはなしで各ウェルに添加した。取り込みを、上記細胞を固定したときに30分間にわたって進め、共焦点顕微鏡検査法のために調製した。細胞を、4% PFA中で10分間、室温において固定した。次いで、細胞を、PBS中で3回洗浄し、DAPI(PBS中300nM)で5分間染色し、PBS中でさらに2回洗浄した。次いで、カバースリップを、Fluoromount G封入媒体を使用してガラススライド上に載せ、室温において少なくとも24時間シールさせ、その後、画像化した。共焦点顕微鏡検査法を、Nikon A1R Spectralを使用して行い、画像処理を、Nikon Elements and Fijiソフトウェアで行った。
PBS中に懸濁したLC HDL NPおよびAu HDL NP(250nM)を、PBS中で、LCAT(10nM)および遊離コレステロール(100μg/mL)とともに37℃で15時間、300rpmにおいてThermoMixerで振盪してインキュベートした。次いで、サンプルを、10,000gで10分間、50kDaスピンカラムを通して3回遠心分離して、過剰な結合していないコレステロールを除去した。次いで、サンプルを、1×Reaction Buffer中で100倍希釈し、その後、Amplex Red Cholesterol Assay(Thermo Fisher)で定量した。Amplex Red Cholesterol Assayを、製造業者の指示に従って行った。簡潔には、コレステロール標準曲線を、8μg/mLから125ng/mLまで、キットが提供する水性緩衝液においてコレステロールを段階希釈し、96ウェル黒色底マイクロプレートに50μl添加することによって調製した。50μlのサンプルもまた、そのマイクロプレートの各ウェルに三連で添加した。2セットのAmplex Red反応混合物を、コレステロールエステラーゼありおよびなしで調製した。次いで、50μlのAmplex Red反応混合物を各ウェルに添加した。マイクロプレートを、37℃で1時間または蛍光シグナルが低下し始めるまでインキュベートした。
NF-kB活性実験のために、THP1-Dual細胞を、QUANTI-Blue分泌型胚性アルカリホスファターゼ(SEAP)検出キット(Invivogen)とともに使用した。THP1-Dual細胞を、10% FBSを含むRPMI中で懸濁して培養し、実験で使用する前に少なくとも2回継代した。THP1-Dual細胞を、96ウェルプレートにおいて100,000細胞/ウェルでプレートした。リポポリサッカリド(LPS)(5ng/mL)を使用して、NF-kB活性を刺激した。実験ウェルを、ナノ粒子またはコントロールを添加する1時間前にLPSで処理した。次いで、検出前に、細胞を、粒子またはコントロールとともに24時間インキュベートした。QUANTI-Blue溶液を、エンドトキシン非含有水中でパケットの中身を溶解し、37℃で30分間インキュベートすることによって調製した。QUANTI-Blue溶液(180μL)を96ウェルプレートにおいて各ウェルに添加した。次いで、THP1-Dual細胞上清(20μL)を、そのQUANTI-Blue溶液に添加し、そのプレートを37℃で2~4時間インキュベートした。SEAPレベルを、Synergyプレートリーダーを使用して650nmの吸光度を検出することによって定量した。
本明細書で開示される特徴の全ては、任意の組み合わせにおいて組み合わせられ得る。本明細書で開示される各特徴は、同じ、等価な、または類似の目的に役立つ代替の特徴によって置き換えられ得る。従って、別段明示的に述べられなければ、開示される各特徴は、一般的な一連の等価なまたは類似の特徴の例に過ぎない。
いくつかの本発明の実施形態が、本明細書で記載および例証されてきたが、当業者は、その機能を果たすならびに/または結果および/もしくは本明細書で記載される利点のうちの1もしくはこれより多くを得るために、種々の他の手段および/または構造を容易に想定し、このようなバリエーションおよび/または改変の各々は、本明細書で記載される発明の実施形態の範囲内であるとみなされる。より一般的には、当業者は、本明細書で記載される全てのパラメーター、寸法、材料、および構成は例示であることが意味され、実際のパラメーター、寸法、材料、および/または構成は、本発明の教示が使用される具体的適用に依存することを容易に認識する。当業者は、慣用的な実験のみを使用して、本明細書で記載される具体的な発明の実施形態に対する多くの均等物を認識するか、または確認し得る。従って、前述の実施形態が、例示によって示されるに過ぎず、添付の特許請求の範囲およびその均等物の範囲内で、発明の実施形態が、具体的に記載され、特許請求されるとおり以外の別の方法で実施され得ることは、理解されるべきである。本開示の発明の実施形態は、本明細書で記載される各個々の特徴、システム、物品、材料、キット、および/または方法に関する。さらに、2またはこれより多くのこのような特徴、システム、物品、材料、キット、および/または方法の任意の組み合わせは、このような特徴、システム、物品、材料、キット、および/または方法が互いに矛盾しなければ、本開示の発明の実施形態の発明の範囲内に含まれる。
Claims (51)
- 球状高密度リポタンパク質ナノ粒子(HDL-NP)であって、コアおよび前記コアを取り囲みかつそれに付着したシェルを含み、ここで前記コアは、脂質結合体化有機性コア足場を含む、HDL-NP。
- 前記シェルは、脂質シェルである、請求項1に記載の球状HDL-NP。
- 前記シェルは、脂質二重層または単層である、請求項1~2のいずれか1項に記載の球状HDL-NP。
- 前記球状HDL-NPは、約-20ミリボルト(mV)の表面ζ電位を有する、請求項1~3のいずれか1項に記載の球状HDL-NP。
- 前記有機性コア足場は、疎水性低分子-リン脂質結合体(PL4)を含む、請求項1~4のいずれか1項に記載の球状HDL-NP。
- 前記PL4は、ヘッド基改変リン脂質を含む、請求項5に記載の球状HDL-NP。
- 前記ヘッド基改変リン脂質は、環ひずみアルキン、1,2-ジパルミトイル-sn-グリセロ-3-ホスホエタノールアミン-N-ジベンゾシクロオクチルを含む、請求項6に記載の球状HDL-NP。
- 前記リン脂質は、複数の末端官能基を有する前記低分子にカップリングされる、請求項6~7のいずれか1項に記載の球状HDL-NP。
- 前記低分子は、テトラキス(4-アジドフェニル)メタンである、請求項8に記載の球状HDL-NP。
- 前記複数の官能基は、2~6個の官能基である、請求項8または9に記載の球状HDL-NP。
- 前記複数の官能基は、4個の官能基である、請求項8または9に記載の球状HDL-NP。
- 前記官能基は、末端アジド(SM-Az)である、請求項8~11のいずれか1項に記載の球状HDL-NP。
- 前記有機性コア足場は、両親媒性DNA連結低分子-リン脂質結合体(DNA-PL4)を含む、請求項1~4のいずれか1項に記載の球状HDL-NP。
- 前記DNAは、5~17ヌクレオチド長の2本鎖オリゴヌクレオチドである、請求項13に記載の球状HDL-NP。
- 前記DNAは、8~15ヌクレオチド長の2本鎖オリゴヌクレオチドである、請求項13に記載の球状HDL-NP。
- 前記DNAは、9ヌクレオチド長の2本鎖オリゴヌクレオチドである、請求項13に記載の球状HDL-NP。
- 前記2本鎖DNAの第1の1本鎖は、リン脂質に連結され、ssDNA-リン脂質結合体(ssDNA-PL)を形成する、請求項13~16のいずれか1項に記載の球状HDL-NP。
- 前記2本鎖DNAの前記第1鎖に相補的な前記2本鎖DNAの第2鎖は、低分子に連結される、請求項17に記載の球状HDL-NP。
- 前記低分子は、四面体低分子であり、前記DNAに連結された前記低分子は、四面体低分子-DNAハイブリッド(SMDH4)を形成する、請求項18に記載の球状HDL-NP。
- 前記SMDH4は、前記DNAの相補的な1本鎖の間の水素結合を介して前記ssDNA-PLに連結される、請求項19に記載の球状HDL-NP。
- 前記球状HDL-NPは、約5~30nm、5~20nm、5~15nm、5~10nm、8~13nm、8~12nm、または10nmの直径を有する、請求項1~20のいずれか1項に記載の球状HDL-NP。
- 前記球状HDL-NPは、金コアを有する合成HDLナノ粒子よりヒトHDLに近いζ電位を有する、請求項1~21のいずれか1項に記載の球状HDL-NP。
- 前記ζ電位は、-16~-26mVである、請求項22に記載の球状HDL-NP。
- 前記球状HDL-NPは、アポリポタンパク質または金コアを有する合成HDLナノ粒子のものより効率的なコレステロール輸送能を有する、請求項1~23のいずれか1項に記載の球状HDL-NP。
- アポリポタンパク質をさらに含む、請求項1~24のいずれか1項に記載の球状HDL-NP。
- アポリポタンパク質A-I (ApoA1)をさらに含む、請求項1~25のいずれか1項に記載の球状HDL-NP。
- 前記HDL-NPは、8.7nmより大きい流体力学的直径を有する、請求項1~26のいずれか1項に記載の球状HDL-NP。
- 前記HDL-NPは、8.7nm~17.7nmの流体力学的直径を有する、請求項1~27のいずれか1項に記載の球状HDL-NP。
- 前記HDL-NPは、10nm~15nmの流体力学的直径を有する、請求項1~28のいずれか1項に記載の球状HDL-NP。
- 前記HDL-NPは、12nm~14nmの流体力学的直径を有する、請求項1~29のいずれか1項に記載の球状HDL-NP。
- 前記HDL-NPに連結された治療剤をさらに含む、請求項1~30のいずれか1項に記載の球状HDL-NP。
- 前記治療剤は、治療用核酸である、請求項31に記載の球状HDL-NP。
- 前記治療剤は、抗がん剤である、請求項31に記載の球状HDL-NP。
- 前記抗がん剤は、化学療法剤である、請求項33に記載の球状HDL-NP。
- 前記治療剤は、抗炎症剤である、請求項31に記載の球状HDL-NP。
- 請求項1~35のいずれか1項に記載の球状HDL-NPを含む、薬学的組成物。
- がんを処置するための方法であって、前記方法は、
がんを有する被験体に、コアおよび前記コアを取り囲みかつそれに付着したシェルを含む球状高密度リポタンパク質ナノ粒子(HDL-NP)を投与する工程であって、ここで前記コアは、前記がんを処置するために有効な量で脂質結合体化有機性コア足場を含む、工程、
を包含する、方法。 - 炎症性障害を処置する方法であって、前記方法は、
炎症性障害を有する被験体に、コアおよび前記コアを取り囲みかつそれに付着したシェルを含む球状高密度リポタンパク質ナノ粒子(HDL-NP)を投与する工程であって、ここで前記コアは、前記炎症性障害を処置するために有効な量で脂質結合体化有機性コア足場を含む、工程、
を包含する、方法。 - 前記球状HDL-NPは、請求項1~35のいずれか1項に記載の球状HDL-NPである、請求項37または38に記載の方法。
- 前記被験体は、哺乳動物である、請求項37~39のいずれか1項に記載の方法。
- 前記被験体は、ヒトである、請求項40に記載の方法。
- NF-kB活性を低減する方法であって、前記方法は、被験体に、有効量の、請求項1~35のいずれか1項に記載の球状HDL-NPを含む組成物を投与する工程を包含する、方法。
- 球状高密度リポタンパク質ナノ粒子(HDL-NP)を作製するための方法であって、前記方法は:
ssDNA-リン脂質結合体(ssDNA-PL)を調製する工程、
四面体低分子-DNAハイブリッド(SMDH4)を調製する工程であって、ここで前記ssDNA-PLおよびSMDH4は、相補的DNA配列を有する、工程、
前記ssDNA-PLおよびSMDH4を、前記相補的DNA配列が互いに塩基対合して、DNA-PLコアを形成するようにインキュベートする工程、ならびに
DNA-PLコアリン脂質リポソームおよびアポリポタンパク質に添加して、前記球状HDL-NPを生成する工程、
を包含する、方法。 - 前記ssDNA-PLは、少なくとも9ヌクレオチドのオリゴヌクレオチドを含む、請求項43に記載の方法。
- 前記オリゴヌクレオチドは、9ヌクレオチド長である、請求項44に記載の方法。
- 前記オリゴヌクレオチドは、配列番号1を含む、請求項45に記載の方法。
- 前記SMDH4は、少なくとも9ヌクレオチドのオリゴヌクレオチドを含む、請求項43に記載の方法。
- 前記オリゴヌクレオチドは、9ヌクレオチド長である、請求項47に記載の方法。
- 前記オリゴヌクレオチドは、配列番号3を含む、請求項48に記載の方法。
- 前記アポリポタンパク質は、アポリポタンパク質A-Iである、請求項43~49のいずれか1項に記載の方法。
- 4個の末端アジドを有する四面体低分子コア(テトラキス(4-アジドフェニル)メタン)に連結された1,2-ジパルミトイル-sn-グリセロ-3-ホスホエタノールアミン-N-ジベンゾシクロオクチル(DBCO PE)を含む、有機性コア足場。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962796534P | 2019-01-24 | 2019-01-24 | |
US62/796,534 | 2019-01-24 | ||
PCT/US2020/015109 WO2020154705A1 (en) | 2019-01-24 | 2020-01-24 | High-density lipoprotein mimetic nanoparticles using lipid conjugated core scaffolds |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022518479A true JP2022518479A (ja) | 2022-03-15 |
JPWO2020154705A5 JPWO2020154705A5 (ja) | 2024-05-08 |
Family
ID=71736549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021542150A Pending JP2022518479A (ja) | 2019-01-24 | 2020-01-24 | 脂質結合体化コア足場を使用する高密度リポタンパク質模倣ナノ粒子 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220151928A1 (ja) |
EP (1) | EP3914236A4 (ja) |
JP (1) | JP2022518479A (ja) |
CN (1) | CN113613635A (ja) |
AU (1) | AU2020210881A1 (ja) |
CA (1) | CA3127256A1 (ja) |
MX (1) | MX2021008940A (ja) |
SG (1) | SG11202107156WA (ja) |
WO (1) | WO2020154705A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2787156C (en) | 2010-01-19 | 2020-12-29 | Northwestern University | Synthetic nanostructures for delivery of oligonucleotides |
RS65449B1 (sr) | 2018-10-09 | 2024-05-31 | The Univ Of British Columbia | Supstance i sistemi koji obuhvataju vezikule kompetentne za transfekciju bez organskih rastvarača i deterdženata i metode za to |
AU2021364385A1 (en) * | 2020-10-23 | 2023-06-01 | City Of Hope | Hydrophobic drugs in organic core high density lipoprotein (hdl) nanoparticles |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2750662A4 (en) * | 2011-08-31 | 2015-06-24 | Univ Georgia | NANOPARTICLES TARGETING APOPTOSIS |
DE102014112088A1 (de) * | 2014-08-25 | 2016-02-25 | Karlsruher Institut für Technologie | Verfahren zur Herstellung mikroporöser organischer Membranen, mikroporöse organische Membranen und deren Verwendung |
EP3236955A1 (en) * | 2014-12-22 | 2017-11-01 | University of Georgia Research Foundation Inc. | Nanoparticles for lipid homeostasis |
-
2020
- 2020-01-24 MX MX2021008940A patent/MX2021008940A/es unknown
- 2020-01-24 AU AU2020210881A patent/AU2020210881A1/en active Pending
- 2020-01-24 WO PCT/US2020/015109 patent/WO2020154705A1/en unknown
- 2020-01-24 CN CN202080010616.0A patent/CN113613635A/zh active Pending
- 2020-01-24 JP JP2021542150A patent/JP2022518479A/ja active Pending
- 2020-01-24 SG SG11202107156WA patent/SG11202107156WA/en unknown
- 2020-01-24 CA CA3127256A patent/CA3127256A1/en active Pending
- 2020-01-24 US US17/425,401 patent/US20220151928A1/en active Pending
- 2020-01-24 EP EP20745880.3A patent/EP3914236A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220151928A1 (en) | 2022-05-19 |
CA3127256A1 (en) | 2020-07-30 |
WO2020154705A1 (en) | 2020-07-30 |
EP3914236A4 (en) | 2022-10-26 |
MX2021008940A (es) | 2021-11-04 |
SG11202107156WA (en) | 2021-08-30 |
AU2020210881A1 (en) | 2021-07-22 |
EP3914236A1 (en) | 2021-12-01 |
CN113613635A (zh) | 2021-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022518479A (ja) | 脂質結合体化コア足場を使用する高密度リポタンパク質模倣ナノ粒子 | |
Tian et al. | Potential of exosomes as diagnostic biomarkers and therapeutic carriers for doxorubicin-induced cardiotoxicity | |
Xiao et al. | Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice | |
KR101630888B1 (ko) | 표적 유전자의 발현을 억제하는 조성물 | |
JP2022518207A (ja) | 酸化コレステロールを含有する薬物送達システム | |
US20200281962A1 (en) | Nitric oxide releasing high density lipoprotein-like nanoparticles (no hdl nps) | |
Tang et al. | A simple self-assembly nanomicelle based on brain tumor-targeting peptide-mediated siRNA delivery for glioma immunotherapy via intranasal administration | |
Zhou et al. | Exosome mediated cytosolic cisplatin delivery through clathrin-independent endocytosis and enhanced anti-cancer effect via avoiding endosome trapping in cisplatin-resistant ovarian cancer | |
Wang et al. | Sialic acid conjugate–modified liposomal dexamethasone palmitate targeting neutrophils for rheumatoid arthritis therapy: influence of particle size | |
Ma et al. | Lipid-mediated delivery of oligonucleotide to pulmonary endothelium | |
Tan et al. | Skimmed bovine milk-derived extracellular vesicles isolated via “salting-out”: Characterizations and potential functions as nanocarriers | |
Li et al. | Nanostructure of Functional Larotaxel Liposomes Decorated with Guanine‐Rich Quadruplex Nucleotide–Lipid Derivative for Treatment of Resistant Breast Cancer | |
Pham et al. | Endosomal escape of nucleic acids from extracellular vesicles mediates functional therapeutic delivery | |
Yao et al. | Novel nanotherapeutics for cancer immunotherapy by CTLA-4 aptamer-functionalized albumin nanoparticle loaded with antihistamine | |
Yan et al. | SiATG5-loaded cancer cell membrane-fused liposomes induced increased uptake of albumin-bound chemotherapeutics by pancreatic cancer cells | |
JP2019512297A (ja) | 薬物溶出ステントおよび動脈内注射による一酸化窒素放出リン脂質、リポソーム、および高密度リポタンパク質様ナノ粒子(hdl nsp)の送達 | |
Zhang et al. | Peptide‐Decorated Artificial Erythrocyte Microvesicles Endowed with Lymph Node Targeting Function for Drug Delivery | |
JP2003528908A (ja) | Dおよびlエーテル脂質立体異性体およびリポソーム | |
Gong et al. | Adenosine-modulating synthetic high-density lipoprotein for chemoimmunotherapy of triple-negative breast cancer | |
JP7016084B2 (ja) | 核酸導入用脂質誘導体 | |
US20230414509A1 (en) | Hydrophobic drugs in organic core high density lipoprotein (hdl) nanoparticles | |
Li et al. | T cell/Macrophage Dual-Targeting Biomimetic Triptolide Self-Assembly Nanodrugs For Rheumatoid Arthritis Therapy by Inflammatory Microenvironment Remodeling | |
Zhou et al. | Codelivery of ERCC2 small interfering RNA and cisplatin with macrophage-derived mimetic nanovesicles for enhanced bladder cancer treatment | |
Wang | Rubbery RNA Nanoparticles as Targeted-delivery Platform for Liver Cancer Combination Therapy | |
Zheng et al. | Chemical conjugation mitigates immunotoxicity of chemotherapy via reducing receptor-mediated drug leakage from lipid nanoparticles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230123 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230123 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240216 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20240417 |